Hydroxyzine Bluefish Ab

Hydroxyzine hydrochloride, the active ingredient in Hydroxyzine Bluefish Ab, is a first‑generation H1 antihistamine presented as a strength/form for oral use. It treats allergic skin reactions, anxiety, pre‑operative sedation, and nausea in patients as prescribed. GNH USA supplies Hydroxyzine Bluefish Ab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydroxyzine hydrochloride is used to manage conditions mediated by histamine H1 receptors.

Allergic skin reactions: reduces itching, rash and swelling associated with allergies. Anxiety and tension: provides short‑term anxiolysis and calming effects. Pre‑operative sedation: facilitates patient relaxation before surgical procedures. Nausea and vomiting: alleviates postoperative or motion‑related nausea.

Hydroxyzine may cause a range of adverse reactions.

Common Side Effects: - Drowsiness: feeling of sleepiness or reduced alertness. - Dry mouth: decreased salivation leading to oral discomfort. - Blurred vision: temporary visual disturbances. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatotoxicity: liver enzyme elevations or injury. - Respiratory depression: slowed breathing that may be life‑threatening.

Before prescribing hydroxyzine, consider the following precautions.

Elderly patients: increased sensitivity to sedation and anticholinergic effects. Concomitant CNS depressants: may enhance drowsiness and respiratory depression. Operating machinery or driving: avoid until individual response is known. Pregnancy: safety not established; use only if benefits outweigh risks. Breastfeeding: drug excreted in milk; caution advised. Store below 25°C: keep in original packaging, protect from moisture and light.

Hydroxyzine can interact with several drug classes.

Major Interactions (Avoid): - Alcohol: additive central nervous system depression. - Opioids: heightened risk of profound sedation and respiratory depression. - Other antihistamines: increased anticholinergic burden.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, barbiturates): may enhance sedative effect. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise hydroxyzine plasma concentrations.